SFGH, as the only level 1 trauma hospital for San Francisco, is where the most severely injured trauma patients are treated. As the Director for Trauma Anesthesiology, I am engaged on multiple fronts to improve the individual treatment, systems-based care and the science of acute trauma care. I embrace the critical role of blood product and coagulation management and I have been introducing best practices and new techniques for this at a local and national level. Recognizing that this is a complex endeavor requiring multiple disciplines to work in synergy, I have taken on leadership, investigative and educational roles to fulfill my vision of delivering state of the art, multidisciplinary care to the severely injured patient.
PROPPR -Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as receiving 10 units or more RBCs within the first 24 hours). The goal of PROPPR is to improve the basis on which clinicians make decisions about transfusion protocols for massively bleeding patients.
PROPPR is a Resuscitation Outcomes Consortium (ROC) Protocol. ROC is funded by the National Heart, Lung, and Blood Institute (NHLBI), the United States' Department of Defense (DoD) and the Defence Research and Development Canada. PROPPR will be conducted as a Phase III trial at Level I Adult Trauma Centers in North America.